Crescendo Biologics reaches another milestone in its deal with Takeda
Crescendo Biologics has reached fifth milestone in its deal with Takeda from 2016, for using its Humabody-based therapeutics against targets which Takeda selects.
Pharmaceuticals, Biotechnology and Life Sciences
Crescendo Biologics has reached fifth milestone in its deal with Takeda from 2016, for using its Humabody-based therapeutics against targets which Takeda selects.
The iSpecimen Marketplace® provides researchers with unprecedented technology, enabling precision sourcing of hematopoietic stem and immune cell products from expansive…
Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period 41% of patients on…
BOULDER, Colo.–(BUSINESS WIRE)–OnKure, Inc. today announced the appointment of three key members to its management team, James Winkler, Ph.D. as…
The trial is one of the first CAR T cell trials nationwide to enroll prostate cancer patients DUARTE, Calif.–(BUSINESS WIRE)–#CityofHope—City…
WATERTOWN, Mass.–(BUSINESS WIRE)–FORMA Therapeutics, Inc. (“Company”) announced today the appointments of Todd Shegog as Senior Vice President, Chief Financial Officer…
Growth capital supports current, future innovative product development and commercialization INDIANAPOLIS–(BUSINESS WIRE)–Sexton Biotechnologies announced today that it has raised $5…
First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown…
PARIS–(BUSINESS WIRE)–FeetMe, a medical device company that produces smart medical wearables and digital health services to improve mobility, today announced…
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative…